Welcome to Glenmark | Glenmark

About
US
About
US
- Overview Overview
- Evolution The achievements that highlight our journey
- Governance The tenets of our functioning
- Board of Directors The people who pave the way for a new world
- Executive Team The team who translates vision into reality
- Awards Striving for Excellence
Responsibility
Responsibility
- Our CommunitiesEnriching lives for a healthier and happier world
- Our PlanetOperating responsibly towards a greener planet
- Our PeopleDedicated to the vision of a better world
  - Equal Opportunity for all
  - Employee Health and Safety
- ReportsOur corporate responsibility reports
  - FY 2019
  - FY 2018
  - FY 2017
  - FY 2016
  - FY 2015
  - FY 2014
  - FY 2013
  - FY 2012
  - FY 2011
- FoundationsSpearheading our social initiatives
  - Glenmark Foundation
  - Glenmark Aquatic Foundation
Products
Products
- FormulationsHigh quality branded and generic medicines for global markets
- APIPartner of choice of world’s leading generic companies
  - Glenmark Life Sciences
Investors
Investors
- Latest AnnouncementsFor Investors and Shareholders
- Financial ResultsGrowing from strength to strength
- Shareholders CornerBe a part of the new world
- Reports & PresentationPerformance in numbers

Careers
Careers
- Where
- People
- Inspire
- Possibilities
Media
- NewsroomLatest and archived press releases
- LibraryResources and information

Glenmark during the time of COVID-19

Know more about how Glenmark is staying committed to patient needs, public health and giving back to the society amidst the pandemic.
Read More
Dow Jones Sustainability Emerging Markets Index 2019

Glenmark secures its position in the prestigious Dow Jones Sustainability Emerging Markets Index for the second year in a row
Read More
A new way for a new world

At Glenmark, we believe in enriching lives and making a difference to patients all over the world. We constantly strive to find new ways that pave the way for a healthier tomorrow.
Read More
A new world.
A healthier world.

With offices in over 50 countries, 15 manufacturing facilities in four countries and 3 R&D centres worldwide, we work relentlessly towards improving the quality of life of patients across the globe.
Read More
Discovering advance therapies for a new world

We are creating centers of excellence in dermatology, oncology and respiratory therapy. The effort is to develop advance therapies to enrich the lives of patients worldwide.
Read More
A new way for a new world begins with us

Over 14,000 employees from over 60 nationalities with one mission – Enriching lives worldwide.
Read More

INVESTOR CORNER latest announcements

Glenmark’s Q4 FY 2019-20 Results

Glenmark’s MDA Q4 FY 2019 – 20

Glenmark’s consolidated revenue rises 7.96% to Rs. 27,674.89 Mn. for Q4 FY2019-20

Glenmark introduces Favipiravir (FabiFlu®) for the treatment of mild to moderate COVID-19 in India

Indian regulator approves Favipiravir for the treatment of mild to moderate COVID-19 in India

Q4 FY20 Earnings Call Invitation – June 29, 2020

Know More

July 13, 2020 News Announcement
Glenmark commences 1000 patients Post Marketing Surveillance study with COVID-19 who are administered FabiFlu®
Know More

CAREERS
Glenmark is a leading, research–based global pharmaceutical company
Know More

X

This website uses cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details refer to our Terms of Use Policy.